Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paromomycin/Miltefosine vs AmBisome/Miltefosine for PKDL
NCT03399955Phase 2Unknown
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- May 2018
- Primary completion
- May 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Post kala-azar dermal leishmaniasis (PKDL) comparing Paromomycin + Miltefosine with AmBisome + Miltefosine (2 arms). Primary endpoints: Definitive Cure at 12 months and Incidence of treatment-emergent adverse events at 12 months. Status: unknown.
02
Drugs
paromomycinmiltefosineamphotericin b
03
Conditions
Post kala-azar dermal leishmaniasis (PKDL)
Beyond the preview
Go deeper on NCT03399955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03399955.